Recent News

• 05.28.2026 - Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
• 05.07.2026 - Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update
• 04.27.2026 - Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026
• 03.18.2026 - Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

Recent Filings

• 05.12.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.07.2026 - 8-K Current report
• 05.07.2026 - EX-99.1 EX-99.1
• 05.07.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 04.28.2026 - 8-K Current report
• 04.28.2026 - EX-99.1 EX-99.1
• 04.27.2026 - 4 Statement of changes in beneficial ownership of securities
• 04.27.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 04.23.2026 - ARS Annual Report to Security Holders